Therefore, VIP maintained the intrinsic inhibitory activity of GSK3β and BACE1 and exerted a synergistic anti-dementia therapeutic effect, which was consistent with the improvement in behavioral tests observed in APP/PS1 mice treated with VIP@siScr. Here, BACE1 is linked to dementia.